Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

Juli 1, 2021
Persbericht Gereglementeerde informatie – VOORWETENSCHAP 1 juli 2021, 07:00 CEST   Tussentijdse data van 26 patiënten uit de Roll-In Cohort bevestigen de positieve resultaten voor alle primaire eindpunten[i] Meer dan 90% vermindering in de gemiddelde frequentie van therapeutische paracentese ten opzichte van de baseline Bij alle patiënten was de gemiddelde frequentie van therapeutische paracentese per...
Read More

PERSBERICHTEN

INSCHRIJVEN OP ONZE PERSBERICHTEN